Analysts Are Bullish on Sarepta Therapeutics

Mike Benson - Author

Aug. 7 2018, Updated 9:45 a.m. ET

Wall Street analysts’ estimates

Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in the first quarter. The company’s revenue rose 100% YoY as compared to $16.3 million in the first quarter of 2017. Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017.

The above chart compares analysts’ recommendations over the last 12 months.

Article continues below advertisement

Analysts’ ratings and recommendations

Sarepta’s stock price has risen ~216.1% over the last 12 months and ~118.8% in 2018 year-to-date. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. Analysts have a 12-month target price of $184.53 per share as compared to the last price of $120.87 per share as of August 3.

As of August 6, 19 analysts were tracking Sarepta Therapeutics stock. Of these, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” one analyst recommended a “hold,” and none of the analysts recommended a “sell.” The consensus rating for Sarepta’s stock is 1.74, which represents a “strong buy” for momentum investors and long-term investors.

The Invesco Dynamic Biotechnology & Genome ETF (PBE) holds 3.2% of its total investments in Sarepta Therapeutics (SRPT), 4.6% in Alexion Pharmaceuticals (ALXN), 4.8% in Vertex Pharmaceuticals (VRTX), and 5.2% in Biogen (BIIB).


Latest PowerShares Dynamic Biotech & Genome ETF News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.